Are z-hypnotics better and safer sleeping pills than benzodiazepines?;Er z-hypnotika bedre og tryggere sovemedisiner enn benzodiazepiner?

Tidsskrift for den Norske Laegeforening

Volumn 126, Issue 22, 2006, Pages 2954-2956

  Mellingsæter, Trude C ^a   Bramness, Jørgen G ^b   Slørdal, Lars ^a,c  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b Nasjonalt Folkehelseinstitutt ^*  (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; HYPNOTIC AGENT; ZALEPLON; ZOLPIDEM; ZOPICLONE;

DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; DRUG USE; HANGOVER; HUMAN; PILL; PRESCRIPTION; SHORT SURVEY; SLEEP;

ACETAMIDES; BENZODIAZEPINES; HALF-LIFE; HUMANS; HYPNOTICS AND SEDATIVES; PIPERAZINES; PYRIDINES; PYRIMIDINES; SUBSTANCE-RELATED DISORDERS;

EID: 33751254733     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (12)

1. Sanger DJ. The pharmacology and mechanism of action of new generation, non-benzodiazepine hypnotic agents. CNS Drugs 2004; 18: 9-15.
2. Wagner J, Wagner ML. Non-benzodiazepines for the treatment of insomnia. Sleep Med Rev 2000; 4 (suppl 1): 551-81.
3. Terzano MG, Rossi M, Palomba V et al. New drugs for insomnia. Comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Saf 2003; 26: 261-82.
4. Vermeeren A. Residual effects of hypnotics. Epidemiology and clinical implications. CNS Drugs 2004; 18: 297-328.
5. Holsten F. L5 Legemidler ved psykiske lidelser, L5.1 Anxiolytika og hypnotika. Vilberg A, red. Norsk legemiddelhåndbok for helsepersonell. Oslo: Foreningen for utgivelse av norsk legemiddelhåndbok, 2004: 859-68.
6. Dündar Y, Dodd S, Strobl J et al. Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. Human Psychopharmacol Clin Exp 2004; 19: 305-22.
7. Reith DM, Fountain J, McDowell R et al. Comparison of the fatal toxicity index of zopiclone with benzodiazepines. Clin Toxicol 2003; 41: 975-80.
8. Montplaisir J, Hawa R, Moller H et al. Zopiclone and zaleplon vs benzodiazepines in the treatment of insomnia; Canadian consensus statement. Human Psychopharmacol Clin Exp 2003; 18: 29-38.
9. Allain H, Bentué-Ferrer D, Polard E et al. Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly. A comparative review. Drugs Aging 2005; 22: 749-65.
10. Fleming JA, Bourgouin J, Hamilton P. A sleep laboratory evaluation of the long-term efficacy of zopiclone. Can J Psychiatry 1998; 33: 103-7.
11. Jaffe JH, Bloor R, Crome I et al. A postmarketing study of relative abuse liability of hypnotic sedative drugs. Addiction 2004; 99: 165-73.
12. Hajak G, Müller WE, Wittchen HU et al. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction 2003; 98: 1371-8.